[HTML][HTML] Concurrent genetic alterations and other biomarkers predict treatment efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer: a review
Y Guo, J Song, Y Wang, L Huang, L Sun, J Zhao… - Frontiers in …, 2020 - frontiersin.org
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the
survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR …
survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR …
Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer
Y Zeng, D Yu, W Tian, F Wu - Current opinion in oncology, 2022 - journals.lww.com
Resistance mechanisms to osimertinib and emerging therapeuti... : Current Opinion in
Oncology Resistance mechanisms to osimertinib and emerging therapeutic strategies in …
Oncology Resistance mechanisms to osimertinib and emerging therapeutic strategies in …
Co-delivery of erlotinib and doxorubicin by MoS2 nanosheets for synergetic photothermal chemotherapy of cancer
J Liu, J Zheng, H Nie, H Chen, B Li, L Jia - Chemical Engineering Journal, 2020 - Elsevier
Time-staggered administration of erlotinib (Er) and doxorubicin (DOX) provides significantly
enhanced apoptosis of lung cancer cells, but this administration approach has not been …
enhanced apoptosis of lung cancer cells, but this administration approach has not been …
[HTML][HTML] First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: a systematic …
Q Wu, W Luo, W Li, T Wang, L Huang, F Xu - Frontiers in Oncology, 2021 - frontiersin.org
Objective The aim of this meta-analysis was to evaluate efficacy and toxicity of epidermal
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with …
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with …
[HTML][HTML] Mechanisms of EGFR-TKI-induced apoptosis and strategies targeting apoptosis in EGFR-mutated non-small cell lung cancer
S Nishihara, T Yamaoka, F Ishikawa, K Higuchi… - Genes, 2022 - mdpi.com
Homeostasis is achieved by balancing cell survival and death. In cancer cells, especially
those carrying driver mutations, the processes and signals that promote apoptosis are …
those carrying driver mutations, the processes and signals that promote apoptosis are …
Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy
X Li, D Zhang, B Li, B Zou, S Wang, B Fan, W Li, J Yu… - Lung Cancer, 2021 - Elsevier
Introduction B-cell lymphoma 2-like 11 (BCL-2-like 11, BCL2L11, also known as BIM)
deletion polymorphism (BIM-del) has been associated with resistance to first-generation …
deletion polymorphism (BIM-del) has been associated with resistance to first-generation …
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor …
The year 2024 is the 20th anniversary of the discovery of activating epidermal growth factor
receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Since then, tremendous …
receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Since then, tremendous …
[HTML][HTML] Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of …
T Gong, Q Huang, F Tang, Y Wang, Z Li, Y Luo… - Frontiers in …, 2022 - frontiersin.org
Background Osteosarcoma commonly develops during childhood and adolescence. Only
one-third of osteosarcoma patients have been clinically detected over the age of 40 years …
one-third of osteosarcoma patients have been clinically detected over the age of 40 years …
Progress and future prospective of FDG-PET/CT imaging combined with optimized procedures in lung cancer: toward precision medicine
With a 5-year overall survival of approximately 20%, lung cancer has always been the
number one cancer-specific killer all over the world. As a fusion of positron emission …
number one cancer-specific killer all over the world. As a fusion of positron emission …
EGFR inhibitors plus bevacizumab are superior than EGFR inhibitors alone as first-line setting in advanced NSCLC with EGFR mutations and BIM deletion …
AF Cardona, C Ordóñez-Reyes, A Ruiz-Patiño… - JCO Precision …, 2021 - ascopubs.org
PURPOSE BIM activation is essential for epidermal growth factor receptor (EGFR)-tyrosine
kinase inhibitor (TKI)–triggered apoptosis in EGFR-mutant non–small-cell lung cancer …
kinase inhibitor (TKI)–triggered apoptosis in EGFR-mutant non–small-cell lung cancer …